Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Anika Therapeutics (ANIK) Enterprise Value: 2009-2024

Historic Enterprise Value for Anika Therapeutics (ANIK) over the last 16 years, with Dec 2024 value amounting to $161.8 million.

  • Anika Therapeutics' Enterprise Value fell 79.85% to $55.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$176.3 million, marking a year-over-year decrease of 899.33%. This contributed to the annual value of $161.8 million for FY2024, which is 31.61% down from last year.
  • Per Anika Therapeutics' latest filing, its Enterprise Value stood at $161.8 million for FY2024, which was down 31.61% from $236.7 million recorded in FY2023.
  • Anika Therapeutics' 5-year Enterprise Value high stood at $545.0 million for FY2020, and its period low was $161.8 million during FY2024.
  • Moreover, its 3-year median value for Enterprise Value was $236.7 million (2023), whereas its average is $236.7 million.
  • Data for Anika Therapeutics' Enterprise Value shows a maximum YoY tumbled of 31.61% (in 2024) over the last 5 years.
  • Over the past 5 years, Anika Therapeutics' Enterprise Value (Yearly) stood at $545.0 million in 2020, then dropped by 27.89% to $393.0 million in 2021, then decreased by 20.75% to $311.5 million in 2022, then dropped by 24.02% to $236.7 million in 2023, then slumped by 31.61% to $161.8 million in 2024.